PKIB, Recombinant, Human, aa1-78, His-tag (FLJ23817, PRKACN2)

PKIB, Recombinant, Human, aa1-78, His-tag (FLJ23817, PRKACN2)
Item number Size Datasheet Manual SDS Delivery time Quantity Price
P4210-74.100 100 µg - -

1 - 19 business days

451.00€
 
PKIB, also known as cAMP-dependent protein kinase inhibitor beta, is a member of the... more
Product information "PKIB, Recombinant, Human, aa1-78, His-tag (FLJ23817, PRKACN2)"
PKIB, also known as cAMP-dependent protein kinase inhibitor beta, is a member of the cAMP-dependent protein kinase inhibitor family. This protein may interact with the catalytic subunit of cAMP-dependent protein kinase and act as a competitive inhibitor. At least three alternatively spliced transcript variants encoding the same protein have been reported. Source: Recombinant corresponding to aa1-78 from human PKIB, fused to His-tag at N-terminus expressed in E.coli. AA Sequence: MGSSHHHHHH SSGLVPRGSH MRTDSSKMTD VESGVANFAS SARAGRRNAL PDIQSSAATD GTSDLPLKLE ALSVKEDAKE KDEKTTQDQL EKPQNEEK, Molecular Weight: ~10.6kD (98aa) confirmed by MALDI-TOF, Storage and Stability: May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for at least 6 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
Keywords: PKI-beta, cAMP-dependent protein kinase inhibitor beta
Supplier: United States Biological
Supplier-Nr: P4210-74

Properties

Conjugate: No
MW: 10,6 kD
Format: Highly Purified

Handling & Safety

Storage: -20°C
Shipping: +4°C (International: +4°C)
Caution
Our products are for laboratory research use only: Not for administration to humans!
You will get a certificate here
or to request a certificate of analysis.
Read, write and discuss reviews... more
Customer review for "PKIB, Recombinant, Human, aa1-78, His-tag (FLJ23817, PRKACN2)"
Write a review
or to review a product.
Information about the product reference will follow. more
Viewed